SCHEMBL8535706

SCHEMBL8535706

CC1(O)CCNC(c2ccccc2)C1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.50
TSHR P16473 1/20 0.41
KDM1A O60341 4/20 0.39
MAOA P21397 4/20 0.39
MAOB P27338 4/20 0.39
CHRNA7 P36544 1/20 0.39
PRCP P42785 1/20 0.36
SLC6A2 P23975 1/20 0.34
ADRA1A P35348 1/20 0.34
HTR2B P41595 1/20 0.34
SLC6A3 Q01959 1/20 0.34
NPSR1 Q6W5P4 3/20 0.34
MAPK1 P28482 1/20 0.34
RECQL P46063 1/20 0.34
USP2 O75604 1/20 0.34
ALDH1A1 P00352 1/20 0.34
TP53 P04637 1/20 0.34
MAPT P10636 1/20 0.34
HPGD P15428 1/20 0.34
ALOX12 P18054 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2706482 1.00 TRPA1 (0.50) TRPA1TSHRKDM1AMAOAMAOB
SCHEMBL2705811 1.00 TRPA1 (0.50) TRPA1TSHRKDM1AMAOAMAOB
SCHEMBL26984276 1.00 TRPA1 (0.50) TRPA1TSHRKDM1AMAOAMAOB
Hydrochloric Acid SCHEMBL27077286 0.98 TRPA1 (0.49) TRPA1TSHRKDM1AMAOAMAOB
Trifluoroacetic Acid SCHEMBL6119973 0.89 KDM1A (0.41) TRPA1TSHRKDM1ANPSR1USP2
Trifluoroacetic Acid SCHEMBL6119912 0.89 KDM1A (0.41) TRPA1TSHRKDM1ANPSR1USP2
SCHEMBL13627524 0.82 KDM1A (0.41) TRPA1TSHRKDM1AMAOAMAOB
SCHEMBL20449165 0.82 KDM1A (0.41) TRPA1TSHRKDM1AMAOAMAOB
SCHEMBL27141826 0.79 KDM1A (0.39) TRPA1TSHRKDM1AMAOAMAOB
SCHEMBL26984165 0.79 KDM1A (0.39) TRPA1TSHRKDM1AMAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332156-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS INC 2025-10-30 US disclosed
EP-4551556-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS Vividion Therapeutics, Inc. (US) 2025-05-14 EP disclosed
EP-4313295-A1 PHARMACEUTICAL COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) Almac Discovery Limited (GB) 2024-02-07 EP disclosed
WO-2024010784-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS VIVIDION THERAPEUTICS, INC. (US) 2024-01-11 WO disclosed
WO-2022200523-A1 PHARMACEUTICALS COMPOUNDS AS INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 19 (USP19) ALMAC DISCOVERY LIMITED (GB) 2022-09-29 WO disclosed
EP-2643316-A2 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE Exelixis, Inc. (US) 2013-10-02 EP disclosed
WO-2012071509-A2 BENZOXAZEPINES AS INHIBITORS OF P13K/MTOR AND METHODS OF THEIR USE AND MANUFACTURE EXELIXIS, INC. (US) 2012-05-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250332156-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING WRN HELICASE INHIBITORS RECQL, BLM, WRN TRPA1 4252/4885TSHR 3832/4885KDM1A 1586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.